- Home
- PDM vs NTLA Comparison
PDM vs NTLA Comparison
Compare PDM & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- NTLA
- Stock Information
- Founded
- PDM 1997
- NTLA 2014
- Country
- PDM United States
- NTLA United States
- Employees
- PDM N/A
- NTLA N/A
- Industry
- PDM Building operators
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PDM Real Estate
- NTLA Health Care
- Exchange
- PDM Nasdaq
- NTLA Nasdaq
- Market Cap
- PDM 1.1B
- NTLA 1.2B
- IPO Year
- PDM N/A
- NTLA 2016
- Fundamental
- Price
- PDM $8.15
- NTLA $12.32
- Analyst Decision
- PDM Buy
- NTLA Buy
- Analyst Count
- PDM 5
- NTLA 20
- Target Price
- PDM $9.40
- NTLA $25.48
- AVG Volume (30 Days)
- PDM 839.1K
- NTLA 10.8M
- Earning Date
- PDM 10-27-2025
- NTLA 11-06-2025
- Dividend Yield
- PDM 3.08%
- NTLA N/A
- EPS Growth
- PDM N/A
- NTLA N/A
- EPS
- PDM N/A
- NTLA N/A
- Revenue
- PDM $565,372,000.00
- NTLA $52,857,000.00
- Revenue This Year
- PDM N/A
- NTLA $9.20
- Revenue Next Year
- PDM N/A
- NTLA N/A
- P/E Ratio
- PDM N/A
- NTLA N/A
- Revenue Growth
- PDM N/A
- NTLA 14.99
- 52 Week Low
- PDM $5.46
- NTLA $5.90
- 52 Week High
- PDM $10.72
- NTLA $28.25
- Technical
- Relative Strength Index (RSI)
- PDM 41.50
- NTLA 33.43
- Support Level
- PDM $7.85
- NTLA $11.63
- Resistance Level
- PDM $8.90
- NTLA $13.60
- Average True Range (ATR)
- PDM 0.23
- NTLA 1.66
- MACD
- PDM -0.03
- NTLA -1.70
- Stochastic Oscillator
- PDM 24.29
- NTLA 3.76
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.